Inhibikase Therapeutics Inc Quick Ratio (IKT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Inhibikase Therapeutics Inc   (NASDAQ: IKT)

Inhibikase Therapeutics Inc 's Quick Ratio

IKT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 15.5 above Inhibikase Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Quick Ratio than Inhibikase Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 93 to 261.

Explain Quick Ratio?
How much Cash & cash equivalents IKT´s has?
What are IKT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IKT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 74.27 % 8.18 % 40.33 % -11.56 % 58.93 %
Y / Y Cash & cash equivalent Change 81.39 % 82.84 % 29.02 % 2283.81 % 1004.1 %
Quick Ratio MRQ 15.5 29.83 34.12 18.08 14.89
IKT's Total Ranking # 261 # 93 # 123 # #
Seq. Current Liabilities Change 79.62 % 9.02 % 22.5 % -27.35 % 11.5 %
Seq. Cash & cash equivalent Change -6.66 % -4.7 % 131.19 % -11.8 % -5.92 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 19
Healthcare Sector # 97
Overall Market # 261


Quick Ratio Statistics
High Average Low
34.12 12.27 0.67
(Dec 31 2025)   (Sep 30 2024)




Financial Statements
Inhibikase Therapeutics Inc 's Current Liabilities $ 10 Millions Visit IKT's Balance sheet
Inhibikase Therapeutics Inc 's Cash & cash equivalent $ 159 Millions Visit IKT's Balance sheet
Source of IKT's Sales Visit IKT's Sales by Geography


Cumulative Inhibikase Therapeutics Inc 's Quick Ratio

IKT's Quick Ratio for the trailling 12 Months

IKT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 29.14 % 20.29 % 27.47 % 23.33 % 46.68 %
Y / Y Cash & cash equivalent TTM Growth 81.46 % 111.64 % 173.96 % 1060.51 % 575.37 %
Quick Ratio TTM 22.97 24.35 21.12 20.69 16.35
Total Ranking TTM # 2950 # 2918 # 2633 # #
Seq. Current Liabilities TTM Growth 20.71 % 2.09 % 7.85 % -2.83 % 12.44 %
Seq. Cash & cash equivalent TTM Growth 13.88 % 17.67 % 10.14 % 22.96 % 32.82 %

Quick ratio ranking by company, industry and sector >> Back to IKT Financial Strength Comparisons >> Go to Compare IKT Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2026 to $10.26 millions, cumulative Quick Ratio decreased to 22.97 above the IKT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 131 other companies have achieved higher Quick Ratio than Inhibikase Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2918 to 2950.

Explain Quick Ratio?
How much Cash & cash equivalents IKT´s has?
What are IKT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 132
Healthcare Sector # 807
Within the Market # 2950


trailing twelve months Quick Ratio Statistics
High Average Low
18.91 9.48 2.1
(Jun 30 2026)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Allogene Therapeutics Inc   35.83 $ 1,136.743  Millions$ 31.727  Millions
Hemab Therapeutics Holdings Inc   35.34 $ 457.460  Millions$ 12.944  Millions
Vor Biopharma Inc   33.22 $ 824.374  Millions$ 24.814  Millions
Lexeo Therapeutics Inc   31.51 $ 494.406  Millions$ 15.692  Millions
Imagenebio Inc   27.03 $ 177.676  Millions$ 6.573  Millions
Beam Therapeutics Inc   26.37 $ 2,133.102  Millions$ 80.883  Millions
Apogee Therapeutics Inc   25.91 $ 971.926  Millions$ 37.510  Millions
Anavex Life Sciences Corp   24.47 $ 118.326  Millions$ 4.836  Millions
Artiva Biotherapeutics Inc   23.96 $ 349.400  Millions$ 14.581  Millions
Palisade Bio Inc   23.86 $ 125.172  Millions$ 5.246  Millions
Pharmacyte Biotech Inc   23.21 $ 17.838  Millions$ 0.769  Millions
Cg Oncology Inc   21.77 $ 1,028.278  Millions$ 47.240  Millions
Instil Bio Inc   21.08 $ 69.678  Millions$ 3.305  Millions
Solid Biosciences Inc   20.85 $ 595.984  Millions$ 28.584  Millions
Relay Therapeutics Inc   17.93 $ 910.934  Millions$ 50.804  Millions
Maze Therapeutics Inc   17.90 $ 411.087  Millions$ 22.961  Millions
Crispr Therapeutics Ag  17.79 $ 2,364.352  Millions$ 132.896  Millions
Taysha Gene Therapies Inc   17.53 $ 455.407  Millions$ 25.975  Millions
Aura Biosciences Inc   16.56 $ 323.840  Millions$ 19.560  Millions
Kalaris Therapeutics Inc   16.46 $ 143.865  Millions$ 8.738  Millions
Kyverna Therapeutics Inc   16.10 $ 367.021  Millions$ 22.802  Millions
Tectonic Therapeutic Inc   15.96 $ 227.068  Millions$ 14.224  Millions
Candel Therapeutics Inc   15.89 $ 201.565  Millions$ 12.685  Millions
Inhibikase Therapeutics Inc   15.50 $ 159.019  Millions$ 10.260  Millions
Voyager Therapeutics Inc   13.75 $ 229.369  Millions$ 16.685  Millions
Leonabio Inc   13.07 $ 102.167  Millions$ 7.817  Millions
Lenz Therapeutics Inc   12.82 $ 220.651  Millions$ 17.212  Millions
X4 Pharmaceuticals Inc  11.41 $ 220.874  Millions$ 19.366  Millions
Quince Therapeutics Inc   11.30 $ 116.000  Millions$ 10.262  Millions
Compass Therapeutics Inc   11.15 $ 179.879  Millions$ 16.128  Millions

Date modified: 2026-09-04T17:23:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.